首页> 美国卫生研究院文献>other >Desktop Transcriptome Sequencing From Archival Tissue to Identify Clinically Relevant Translocations
【2h】

Desktop Transcriptome Sequencing From Archival Tissue to Identify Clinically Relevant Translocations

机译:从档案组织进行桌面转录组测序以鉴定临床相关易位

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Somatic mutations, often translocations or single nucleotide variations, are pathognomonic for certain types of cancers and are increasingly of clinical importance for diagnosis and prediction of response to therapy. Conventional clinical assays only evaluate 1 mutation at a time, and targeted tests are often constrained to identify only the most common mutations. Genome-wide or transcriptome-wide high-throughput sequencing (HTS) of clinical samples offers an opportunity to evaluate for all clinically significant mutations with a single test. Recently a “desktop version” of HTS has become available, but most of the experience to date is based on data obtained from high-quality DNA from frozen specimens. In this study, we demonstrate, as a proof of principle, that translocations in sarcomas can be diagnosed from formalin-fixed paraffin-embedded (FFPE) tissue with desktop HTS. Using the first generation MiSeq platform, full transcriptome sequencing was performed on FFPE material from archival blocks of 3 synovial sarcomas, 3 myxoid liposarcomas, 2 Ewing sarcomas, and 1 clear cell sarcoma. Mapping the reads to the “sarcomatome” (all known 83 genes involved in translocations and mutations in sarcoma) and using a novel algorithm for ranking fusion candidates, the pathognomonic fusions and the exact breakpoints were identified in all cases of synovial sarcoma, myxoid liposarcoma, and clear cell sarcoma. The Ewing sarcoma fusion gene was detectable in FFPE material only with a sequencing platform that generates greater sequencing depth. The results show that a single transcriptome HTS assay, from FFPE, has the potential to replace conventional molecular diagnostic techniques for the evaluation of clinically relevant mutations in cancer.
机译:体细胞突变,通常是易位或单核苷酸变异,对于某些类型的癌症是致病的,对于诊断和预测对治疗的反应越来越具有临床重要性。常规的临床检测一次只能评估一种突变,而定向测试通常只能识别最常见的突变。临床样品的全基因组或转录组范围的高通量测序(HTS)提供了机会,可以通过一次测试评估所有具有临床意义的突变。最近,HTS的“桌面版本”已经可用,但是迄今为止,大多数经验是基于从冷冻样本中获得的高质量DNA所获得的数据。在这项研究中,我们证明作为原理的证明,可以通过台式HTS从福尔马林固定石蜡包埋(FFPE)组织中诊断出肉瘤易位。使用第一代MiSeq平台,对来自3个滑膜肉瘤,3个类固醇脂质肉瘤,2个尤因肉瘤和1个透明细胞肉瘤的档案区的FFPE材料进行了完整的转录组测序。将读段映射到“肉瘤”(所有已知的83个基因参与肉瘤的易位和突变),并使用新颖的算法对融合候选物进行排名,在滑膜肉瘤,粘液状脂肪肉瘤的所有病例中,均确定了病原性融合和确切的断点,并清除细胞肉瘤。仅在产生更大测序深度的测序平台上,在FFPE材料中才能检测到尤因肉瘤融合基因。结果表明,来自FFPE的单转录组HTS分析有可能取代传统的分子诊断技术,以评估癌症的临床相关突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号